drugset
drugset / Trial / NCT05266586

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

NCT05266586 ↗

Phase 2 Completed 119 enrolled NewAmsterdam Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.

Timeline

Start
2022-03-09
Primary completion
2022-08-12
Completion
2022-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg —
Subject Obicetrapib Small molecule 10 mg —

Indications

hyperlipidemia